Aclipse focuses on neurodegenerative and gastrointestinal diseases which are strongly impacted by molecular pathways that regulate cellular stress, protein misfolding and inflammation. M102 targets many relevant disease pathways in amyotrophic lateral sclerosis (ALS) and may be the first potential precision medicine for the treatment of ALS, and M107 is the first potential disease-modifying medicine for the treatment of gastroparesis.
ALS is an incurable and debilitating neurodegenerative conditions that result in progressive degeneration and death of nerve cells, which cause the eventual loss of ability to eat, speak, move and breathe. The heterogeneity and complexity of these disorders have proved major challenges for therapy development. There is an urgent need for effective neuroprotective therapies.
Gastroparesis (GP) is a serious disease affecting stomach nerves and muscles resulting in stomach paralysis and the delayed stomach emptying of foods. Disease symptoms include nausea, vomiting, abdominal pain, stomach fullness, early satiety, and bloating. It is a chronic, often poorly managed condition where all approved drugs treat only symptoms of the disease. GP afflicts approximately 600,000 US patients with a high hospitalization rate. Over 75% of patients classify the disease as severe or very severe and 65% of patients are dissatisfied with current treatments.